Results 131 to 140 of about 189,087 (191)

A post-hoc analysis of intravitreal aflibercept-treated nAMD patients from ARIES & ALTAIR: predicting treatment intervals and frequency for aflibercept treat-and-extend therapy regimen using machine learning. [PDF]

Graefes Arch Clin Exp Ophthalmol
Gutfleisch M, Heimes-Bussmann B, Aydin S, Petrovic R, Loktyushin A, Ohji M, Takahashi K, Okada AA, Scholz P, Youssef H, Bauer-Steinhusen U, Machewitz T, Rothaus K, Lommatzsch A.   +13 more
europepmc   +1 more source

Infiltrating transitional cell carcinoma of the kidney treated by extended nephrectomy

Infiltrating transitional cell carcinoma of the kidney treated by extended nephrectomy
Sixty-three-year-old man, with grosshematuria of four months' duration, was referred to our department. Abdominal ultrasonography suggested right invasive renal pelvic tumor and abdominal CT showed swelling of the right kidney, but renal contour was distinct.
openaire  

One-Year Outcomes of Aflibercept in Treat-and-Extend Versus Pro Re Nata Regimens for Bevacizumab-Resistant Diabetic Macular Edema: A Real-World Study. [PDF]

Ophthalmol Ther
Yozgat Z, Isik MU, Sabaner MC.
europepmc   +1 more source

The Reinforced Treat-and-Extend Protocol for Exudative Age-Related Macular Degeneration: Retrospective Assessment of 24-Month Real-World Outcomes in France. [PDF]

Ophthalmol Ther
Roubelat FP, Barioulet L, Varenne F, Escudier C, Meyer P, Gomane C, Butterworth J, Pagot-Mathis V, Fournié P, Gualino V, Soler V.   +10 more
europepmc   +1 more source

Correction: Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in neovascular age-related macular degeneration (pooled results from TENAYA and LUCERNE). [PDF]

Eye (Lond)
Wijesingha N, Kotecha A, Margaron P, Sivaprasad S.   +3 more
europepmc   +1 more source

Long Intervals between Intravitreal Injections Using a Treat-and-Extend Protocol in a Real-Life Context in AMD: The LIRE Study. [PDF]

Ophthalmologica
Leroux P, Agard E, Billant J, Levron A, Bouvarel H, Badri Y, Douma I, Pradat P, Dot C.   +8 more
europepmc   +1 more source

INFOGRAPHIC: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in diabetic macular oedema (pooled results from YOSEMITE and RHINE). [PDF]

Eye (Lond)
Wijesingha N, Gibson K, Willis JR, Sivaprasad S.   +3 more
europepmc   +1 more source

Impact of treat and extend criteria on proportions that can be extended after loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration: PRECISE Report 5. [PDF]

Eye (Lond)
Thottarath S, Gurudas S, Chandak S, Patel PJ, Kotagiri A, Pearce I, McKibbin M, Menon G, Burton BJL, Talks J, Grabowska A, Ghanchi F, Gale R, Karatsai E, Chandra S, Sivaprasad S.   +15 more
europepmc   +1 more source

Efficacy and Safety of Intravitreal Aflibercept Using a Treat-and-Extend Regimen For Neovascular Age-Related Macular Degeneration-The Aries Study: A Randomized Clinical Trial-Erratum. [PDF]

Retina, 2022
europepmc   +1 more source

Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing. [PDF]

Adv Ther
Kodjikian L, Arias Barquet L, Papp A, Kertes PJ, Midena E, Ernest J, Silva R, Schmelter T, Niesen T, Leal S.   +9 more
europepmc   +1 more source